About Us - STACKLY Biotech

Our Mission & Vision

Driving innovation in biotechnology to transform patient care

Our Mission

To advance healthcare through cutting-edge biotechnology, developing innovative solutions that improve patient outcomes and address the world's most challenging medical conditions.

Our Vision

To be the global leader in biotechnology innovation, transforming the future of medicine through groundbreaking research, ethical practices, and collaborative partnerships.

Our Values

The principles that guide our work and define our culture

Innovation

We push the boundaries of science and technology to develop breakthrough solutions that address unmet medical needs.

Collaboration

We believe in the power of partnerships, working with researchers, clinicians, and patients to advance healthcare together.

Integrity

We maintain the highest ethical standards in all our research, development, and business practices.

Patient-Centered

Our work is always guided by the needs of patients, with the goal of improving lives and health outcomes.

Our Journey

Milestones in our growth and development

2010

STACKLY Biotech was founded by Dr. Elena Rodriguez with a vision to revolutionize genomic medicine.

2013

Launched our first product, GeneSeq Basic, establishing our presence in the genomic sequencing market.

2015

Expanded research facilities and established partnerships with three major research universities.

2017

Received FDA approval for our first diagnostic kit, marking our entry into clinical applications.

2019

Opened European headquarters in Berlin, expanding our global reach and research collaborations.

2021

Launched our breakthrough immunotherapy platform, advancing cancer treatment options.

2023

Celebrated our 500th research publication and expanded into stem cell therapeutics.

Leadership Team

Meet the experts guiding our vision and innovation

Dr. Elena Rodriguez

Founder & CEO

Dr. Rodriguez founded STACKLY Biotech with a vision to transform healthcare through genomic medicine. With over 20 years of experience in biotechnology research, she leads our strategic direction and innovation initiatives.

Dr. James Chen

Chief Scientific Officer

Dr. Chen oversees all research and development activities at STACKLY. His expertise in immunology and gene therapy has been instrumental in developing our innovative therapeutic platforms.

Dr. Sarah Johnson

VP of Research

Dr. Johnson leads our genomic medicine division, focusing on developing advanced sequencing technologies and bioinformatics tools. She has published over 50 peer-reviewed papers in the field.